13
Oct 2026
New research indicates that 5% of practising physicians report a disability "always or often," and another 12% report disability "sometimes." The authors call for action on improving accessibility to ensure equity and sustainability in the physician workforce.
13
Oct 2026
Explore how laboratory vibration can affect sensitive IVF procedures and how vibration surveys and passive isolation can help minimize disruption.
13
Oct 2026
Two newly published studies from Imperial Brands scientists have provided further evidence that products associated with lower levels of combustion-related toxicants also produce substantially lower levels of combustion-related toxicants also produce substantially lower biological activity than cigarette smoke under laboratory conditions.
13
Oct 2026
Canada's proposed Safe Social Media Act, which aims to protect children, should be passed, according to an Analysis article in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.261104.
13
Oct 2026
Canada's proposed Safe Social Media Act, which aims to protect children, should be passed, according to an Analysis article in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.261104.
13
Oct 2026
Researchers at Chalmers University of Technology, in Sweden, shed new light on the remaining risk of heart disease, even after the known risk factor of ‘bad’ cholesterol is brought down to a healthy level.
13
Oct 2026
Bedfont®, a world leader in breath analysis, announces its acquisition of coVita™, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion.
13
Oct 2026
Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribed $18 million USD seed financing.
13
Oct 2026
Bedfont®, a world leader in breath analysis, announces its acquisition of coVitaTM, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion.
13
Oct 2026
Mursla Bio, a precision medicine and diagnostics company built on tissue-specific extracellular vesicles (TS-EVs), today announced publication of a peer-reviewed study in the Journal of Extracellular Vesicles (impact factor 21.7), the founding journal of the International Society for Extracellular Vesicles. This validates the TS-EV platform for a new class of liquid biopsy: the multiomic disease biology of living cells in a chosen tissue, read from blood, starting with the liver.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
